Virax Biolabs Group (VRAX) Competitors $2.04 -0.03 (-1.45%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VRAX vs. NAII, ICCC, EYEN, ITRM, BIVI, PLUR, BGXX, INKT, IBIO, and LSBShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Natural Alternatives International (NAII), ImmuCell (ICCC), Eyenovia (EYEN), Iterum Therapeutics (ITRM), BioVie (BIVI), Pluri (PLUR), Bright Green (BGXX), MiNK Therapeutics (INKT), iBio (IBIO), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Natural Alternatives International ImmuCell Eyenovia Iterum Therapeutics BioVie Pluri Bright Green MiNK Therapeutics iBio Lakeshore Biopharma Natural Alternatives International (NASDAQ:NAII) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Do institutionals and insiders believe in NAII or VRAX? 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 20.9% of Natural Alternatives International shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer NAII or VRAX? Natural Alternatives International received 252 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformNatural Alternatives InternationalOutperform Votes25275.22% Underperform Votes8324.78% Virax Biolabs GroupN/AN/A Do analysts prefer NAII or VRAX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AVirax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has stronger earnings and valuation, NAII or VRAX? Virax Biolabs Group has lower revenue, but higher earnings than Natural Alternatives International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$113.80M0.25-$7.22M-$1.23-3.70Virax Biolabs Group$160K41.18-$6.73MN/AN/A Does the media prefer NAII or VRAX? In the previous week, Natural Alternatives International had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Virax Biolabs Group. Natural Alternatives International's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score. Company Overall Sentiment Natural Alternatives International Neutral Virax Biolabs Group Neutral Is NAII or VRAX more profitable? Virax Biolabs Group has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.34%. Virax Biolabs Group's return on equity of 0.00% beat Natural Alternatives International's return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.34% -8.47% -4.57% Virax Biolabs Group N/A N/A N/A Which has more risk and volatility, NAII or VRAX? Natural Alternatives International has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. SummaryVirax Biolabs Group beats Natural Alternatives International on 7 of the 11 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.59M$2.31B$5.40B$8.53BDividend YieldN/A0.69%5.15%4.14%P/E RatioN/A4.54113.7615.14Price / Sales41.1841.611,483.0493.53Price / CashN/A16.3539.7134.04Price / Book1.023.164.665.01Net Income-$6.73M$29.98M$119.06M$225.46M7 Day Performance-10.53%-3.56%0.79%0.37%1 Month Performance10.27%-0.60%5.65%3.57%1 Year Performance-21.54%-2.99%36.80%29.42% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group0.3193 of 5 stars$2.04-1.4%N/A-18.6%$6.59M$160,000.000.005NAIINatural Alternatives International0.9904 of 5 stars$4.66+2.2%N/A-24.4%$28.89M$113.80M-3.79290Analyst ForecastGap DownICCCImmuCell0.6653 of 5 stars$3.67+2.2%N/A-29.9%$28.67M$23.22M-6.9275Positive NewsEYENEyenovia2.9297 of 5 stars$0.53-3.6%$12.00+2,168.4%-63.9%$28.50M$31,405.00-0.6640Gap DownITRMIterum Therapeutics2.8229 of 5 stars$1.21-16.6%$5.00+313.2%+67.1%$27.47MN/A-0.6110Gap UpHigh Trading VolumeBIVIBioVie2.5596 of 5 stars$2.84+10.9%$4.00+40.8%-39.8%$26.51MN/A-0.2110Gap UpHigh Trading VolumePLURPluri0.8969 of 5 stars$4.81+4.6%N/A+14.4%$26.31M$330,000.00-0.81150Gap DownBGXXBright GreenN/A$0.14flatN/A-63.5%$26.02MN/A-2.282Gap DownINKTMiNK Therapeutics2.0953 of 5 stars$0.72-1.4%$9.00+1,148.3%-30.5%$25.04MN/A-1.4730News CoverageIBIOiBio1.0468 of 5 stars$2.72-2.9%$4.30+58.1%N/A$24.86M$225,000.000.00100LSBLakeshore Biopharma0.3962 of 5 stars$2.58-4.1%N/AN/A$24.01M$573.42M0.00773News CoverageGap Up Related Companies and Tools Related Companies Natural Alternatives International Competitors ImmuCell Competitors Eyenovia Competitors Iterum Therapeutics Competitors BioVie Competitors Pluri Competitors Bright Green Competitors MiNK Therapeutics Competitors iBio Competitors Lakeshore Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRAX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRAX Stock Alerts